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Background: Few studies have analyzed the clinical and echocardiographic differences between light-chain
(AL) and transthyretin (TTR) amyloidosis.
Hypothesis: The aim of the present research was to compare, in a real-world setting, the clinical and echocardio-
graphic profiles of these kinds of amyloidosis, at the time of diagnosis, using new-generation echocardiography.
Methods: Seventy-nine patients with AL and 48 patients with TTR amyloidosis were studied.
Results: According to the criterion of mean left ventricular (LV) thickness >12 mm, 45 AL (C-AL) and all TTR
patients had cardiac amyloidotic involvement, whereas 34 AL patients did not. TTR patients had increased right
ventricular (RV) and LV chambers with increased RV and LV wall thickness and reduced LV ejection fraction
and fractional shortening. Furthermore, TTR patients showed lower N-terminal pro Brain Natriuretic Peptide
concentrations and New York Heart Association functional class when compared with C-AL.
Conclusions: Our data show that at time of first diagnosis, TTR patients have a more advanced amyloidotic
involvement of the heart, despite less severe symptoms and biohumoral signs of heart failure. We can
hypothesize that we observed different diseases at different stages. In fact, AL amyloidosis is a multiorgan
disease with quick progression rate, that becomes rapidly symptomatic, whereas TTR amyloidosis might have
a slow progression rate and might remain poorly symptomatic for a greater amount of time.
Introduction
Systemic amyloidoses are rare diseases characterized by
extracellular deposition of protein-derived fibrils in various
tissues and organs, including the heart.1,2 Amyloidosis
classification is based on the protein composition of
the fibrils and on its clinical features. Among this
wide and diversified spectrum, the 2 most frequent and
clinically challenging etiologies are the immunoglobulin
light-chain (AL) form, and transthyretin-related (ATTR)
form. The ATTR form can be further classified in
hereditary transthyretin-related amyloidosis (ATTRm), due
to mutations in the gene codifying for transthyretin, and
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systemic senile amyloidosis, a noninherited form caused by
the deposition of the wild-type transthyretin (TTR) protein
(ATTRwt) in the extracellular space.2 Cardiac involvement is
frequent in both AL and ATTR amyloidosis, and is associated
with important clinical and psychological consequences3,4
that have a significant impact on prognosis.5
In recent years, authors have focused their attention on
the cardiac involvement of the AL form, assessing, by means
of echocardiography, both left ventricular (LV) and right
ventricular (RV) dysfunction and their consequences on
prognosis.6–11 On the other hand, less attention has been
paid to LV and RV involvement and dysfunction in patients
affected by TTR amyloidosis. This discrepancy might be
due to the low incidence of the disease in nonendemic areas,
to the wide variability of the clinical spectrum associated
with different genetic mutations, and to the geographical
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distribution of this form.12 On the other hand, ATTRwt-
induced heart failure (HF) in the elderly is likely to be both
an underdiagnosed and misdiagnosed clinical entity.
Furthermore, clinical research has been mainly limited to
patients with ATTRm with single mutation,13–15 and only 1
study performed a comprehensive phenotypic evaluation of
different ATTRm mutations in a wide area.16
Despite the wide clinical heterogeneity between AL- and
TTR-related forms, only a few studies, based on small
populations, analyzed the clinical and echocardiographic
differences between AL and TTR amyloidosis.17–19 Ng
et al, comparing patients affected by either ATTRwt or AL
amyloidosis matched for HF New York Heart Association
(NYHA) functional class, showed that the former group
had thicker LV walls despite comparable LV systolic and
diastolic function, at least when assessed by the traditional
echocardiographic evaluation.18 On the other hand, Ogiwara
and coauthors demonstrated that, when matched for LV
wall thickness, ATTRm patients presented less-impaired LV
longitudinal systolic function as assessed by tissue Doppler
imaging (TDI)-derived strain, when compared with patients
affected by AL amyloidosis.19
A single, multicenter, longitudinal study5 compared, at
the time of first diagnosis, the structural and functional
characteristics of a large group of patients with AL or
TTR-related cardiac amyloidosis, based on traditional
echocardiography evaluation and, consequently, without
any insight on myocardial deformation and strain analysis.
All these studies were focused mainly on LV structure
and systo-diastolic function, with scarce attention to the
involvement of the right ventricle.
Recently, TDI and 2-dimensional speckle-tracking
echocardiography have enabled clinicians and researchers
to perform a more careful and accurate evaluation of the
systolic and diastolic function of both ventricles. For these
reasons, we performed the present single-center investiga-
tion, aiming at comparing in a real-world setting, the clinical
and echocardiographic profiles of the 2 most common types
of amyloidosis, at time of diagnosis, by means of the new
generation of echocardiographic technologies.
Methods
Seventy-nine consecutive AL amyloidosis patients, diag-
nosed between March 2006 and August 2013 at the Regional
Referral Centre for Amyloidosis (Florence, Italy) were
compared with 48 consecutive ATTR amyloidosis patients
diagnosed over the same lapse of time in the same center. All
participants gave their informed written consent according
to the Helsinki declaration.
Diagnosis of AL amyloidosis was made by means of
biopsy of an involved organ, demonstrating the typical
Congo red birefringence when viewed under polarized
light. Sites of positive biopsy were abdominal fat in 56
patients (70%), kidneys in 14 (18%), salivary glands in 7
(9%) and the myocardium in 2 (3%). All positive biopsies
showed the typical Congo red birefringence under polarized
light. AL amyloidosis was confirmed by the finding of
either a monoclonal protein in patients’ serum or urine,
or a monoclonal population of plasma cells in the bone
marrow, after immunohistochemistry evaluation, in the
absence of any TTR mutation at DNA analysis. In 2
cases of sole myocardial involvement, electron microscopy
with immunogold labeling was necessary to unambiguously
characterize the nature of the amyloid fibrils.
The diagnosis of ATTRm amyloidosis was based on
the biopsy of abdominal fat in 10 patients (52%), of the
myocardium in 6 (32%), of salivary glands in 3 (16%),
and, since 2009, by positive 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid (99mTc-DPD) scintigraphy (15
patients). Genotype data were available for all 19 patients
with ATTRm; mutations were Ile68Leu (n = 11 patients,
62%), Val122Ile (n = 5 patients, 28%), Glu54Val (n = 1
patient), Gly57Arg (n = 1 patient), and Phe64Leu (n = 1
patient). All 15 patients who underwent 99mTc-DPD
scintigraphy showed the characteristic increase in the
myocardial uptake of the bone tracer, further confirming
the diagnosis of TTR-related cardiac amyloidosis.16
Finally, the diagnosis of ATTRwt amyloidosis (29 patients)
was made by tissue biopsy or by positive 99mTc-DPD
scintigraphy, in the absence of TTR mutation and of
plasma cells dyscrasia. A total of 19 patients (66%) had
histological proof of ATTR amyloidosis by Congo red and
immunohistochemical staining of the myocardium (n = 6,
31%) or other tissues (n = 13, 69%, abdominal fat in 6 patients,
carpal tunnel biopsy in 4, and salivary glands in 3). In 10
(34%) patients affected by definite TTRwt despite negative
tissue biopsy, cardiac amyloidosis was defined as intense
99mTc-DPD uptake in the heart (grade 2 or 3, as defined by
Perugini et al20) in the absence of a plasma cell dyscrasia
and of TTR mutation; in the last group of patients, cardiac
magnetic resonance imaging was performed and showed
the presence of late gadolinium enhancement, which is
consistent with the amyloid involvement of the myocardium.
All participants underwent a thorough clinical evaluation
at the entry visit. In addition, the concentration of N-terminal
pro-brain natriuretic peptide (NT-proBNP) was measured
by an electrochemiluminescence sandwich immunoassay
(Roche Diagnostics, Indianapolis, IN) in the central
hospital laboratory, whereas troponin I was analyzed by
an immunochemiluminescence assay, using a Centaur
XP system (Siemens Healthcare, Erlangen, Germany).
Creatinine clearance was estimated by the Modification
of Diet in Renal Disease (MDRD) formula.21 Both systolic
and diastolic arterial blood pressure were recorded.
A criterion of exclusion from the study was the presence of
any comorbidity that might have caused the increase of LV
wall thickness, such as long-standing arterial hypertension
or moderate-to-severe aortic valve stenosis.
Patients were classified as affected by echocardiography
detectable cardiac AL amyloidosis if the mean value of LV
wall thickness (half of the sum of LV septum and posterior
wall thickness) was >12 mm, and as not having cardiac
involvement if this criterion was not satisfied.22 As there
is currently no published consensus for ATTR amyloidosis,
the same echocardiographic criteria were used for these
patients.
Standard and TDI Echocardiography
At the time of diagnosis, patients were referred to our
echo lab for a complete evaluation, including M-mode,
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2-dimensional, conventional, tissue Doppler, and speckle
strain echocardiography. All the exams were performed by
a single experienced operator (F.C.), who was blinded to
patients’ clinical history, using a Vivid 7 System (Vingmed;
General Electric, Horten, Norway) equipped with a 3S probe.
At least 3 consecutive beats were recorded, and images were
digitized and analyzed off-line. According to the standards of
the American Society of Echocardiography,23 the following
parameters were assessed: end-diastolic thickness of both
ventricular septum (IVS) and LV posterior wall (PW),
LV end-diastolic and end-systolic diameters (LVEDD and
LVESD, respectively), body surface area (BSA), indexed
LV mass (LVmassind), LV endocardial fractional shortening
(FS), left atrial area (LA area, evaluated from the apical
4-chamber view at the end of systole), LV end-diastolic
volume and LV end-systolic volume (LVESV), ejection
fraction (EF, estimated with the biplane Simpson method),
mitral peak flow velocity in early and late diastole (E
and A, respectively, during atrial contraction), E wave
Deceleration Time (DT), E/A ratio, ejection time of the
aortic valve and of the pulmonary valve, LV and RV
myocardial performance index (MPI)—defined as the sum
of isovolumic contraction and relaxation times divided
by the ejection time, as previously described 24 —RV
free wall thickness (RVFW), RV end-diastolic diameter
(RVEDD, evaluated from the parasternal long-axis view),
and the systolic displacement of the lateral portion of the
tricuspid annular plane (TAPSE). LV mass indexed to BSA
was calculated using a previously described formula for
hypertensive patients LVmass: 0.8 × 1.04 × (LVEDD + IVST
+ LVPWT)3 − LVEDD3) + 0.6)/BSA.25
Pulmonary artery systolic pressure (PASP) was approxi-
mated by adding to the transtricuspid pressure gradient an
estimate of right atrial pressure. We also evaluated pulsed
TDI-derived early diastolic peak velocity at lateral mitral
annulus (E′), as an index of LV relaxation, and E/E′ ratio,
as index of LV filling pressure. Transtricuspid peak flow
velocity in early and late diastole (E tricuspid and A tri-
cuspid, respectively) and their ratio were also measured.
Lateral tricuspid annulus pulsed TDI-derived early diastolic
and systolic peak velocities (E′, S′ respectively), and the
E/E′ ratio, as an index of the RV filling pressure, were also
assessed.
By means of 2-dimensional speckle tracking echocardiog-
raphy, LV longitudinal peak systolic strain (LV long strain),
expressed as the average of the 3apical views, and RV (RV
long strain) longitudinal peak systolic strain, expressed as
the average of measurement of the 3 free wall segments in
the apical 4-chamber view, were evaluated.
Statistical Analysis
Statistical analysis was conducted using the SPSS for
Windows package version 13 (SPSS Inc., Chicago, IL).
Categorical and continuous variables were expressed as fre-
quencies (percentages) and as mean ± standard deviation,
respectively. Categorical comparisons were performed by
means of the Pearson χ2 test, whereas the 1-factor analysis
of variance (ANOVA) was used for comparisons between
groups. Post hoc analyses were performed using the Scheffe
method. A 2-tailed P value <0.05 was considered statistically
significant.
Interobserver variability was assessed for LV long strain,
RV long strain, mitral annulus E′ and tricuspid annulus E′
and S′, in 20 randomly selected patients, and calculated
as the standard deviation of the differences between
the measurements of 2 independent observers who were
unaware of any other patient’s data; this variability was
expressed as percentage of the average value.
Results
The population of the study included 79 patients with
systemic AL amyloidosis and 48 patients with TTR-related
amyloidosis. According to international criteria, 45 AL
patients (57%) had cardiac amyloidosis (C-AL group),
whereas the other 34 did not have echocardiographic
evidence of cardiac involvement (NC-AL group). Among
patients with TTR-related amyloidosis, 29 had ATTRwt. All
mutations presented a main cardiac phenotype, and in all
cases but 2 (1 patient with glu54val and 1 patient with
phe64leu), the diagnostic route was cardiologic.
Two patients, 1 with ATTRwt and 1 with ATTRm, had
an incidental diagnosis, due to the unexpected 99mTc-DPD
myocardial uptake at a scintigraphic examination performed
as part of the oncologic follow-up of prostatic neoplasm.
All patients with TTR-related amyloidosis presented
echocardiographic evidence of cardiac involvement at
diagnosis. Clinical and biohumoral characteristics were
reassumed in Table 1.
Left Ventricular Dimension and Function
The results of the ANOVA analysis are summarized in
Table 2. TTR patients showed a significant increase in
LVESD and LVESV, associated to the reduction of EF. A
progressive increase in IVS and PW thickness, LVmassind,
and LA area was observed between groups, with lower mean
values in NC-AL patients, and higher mean values in the
ATTR group. FS was significantly reduced in TTR patients,
compared to other groups. LV MPI and LV longitudinal
strain were significantly impaired in both C-AL and TTR
groups.
As to the evaluation of the diastolic function, both C-AL
and TTR patients showed reduced A and E′ values, with
increase in the E/E′ ratio, compared to the NC-AL group.
Moreover, a progressive increase in the E/A ratio was
observed in the 3 groups, the mean values being significantly
lower in NC-AL patients and higher in TTR patients.
RV Dimension and Function
As reported in Table 3, RVEDD was significantly increased
in TTR patients, whereas a progressive increase in
RVFW was evidenced between groups, mean values being
significantly lower in NC-AL patients and higher in TTR
patients. No difference was observed across groups at
traditional Doppler diastolic evaluation, whereas at tricuspid
annulus TDI analysis, TTR and C-AL subjects showed
significantly lower E′ values with increased E/E′ ratios.
RV systolic function was significantly impaired in TTR and
C-AL patients at traditional, TDI and 2-dimensional speckle
tracking evaluation (TAPSE, S′, and RV longitudinal strain,
respectively). RV MPI was significantly reduced in TTR
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Table 1. Demographic, Clinical, and Biohumoral Characteristics of the Studied Population
NC-AL, N = 34 C-AL, N = 45 TTR, N = 48 P
Age, y 69.4 ± 10.4 68.2 ± 10.2 75.8 ± 9.7a <0.001
Gender, M/F 21 (62%)/13 (38%) 23 (51%)/22 (49%) 40 (83%)/8 (17%) <0.0001
BSA, m2 1.7 ± 0.16 1.7 ± 0.14 1.8 ± 0.14 <0.20
GFR, mL/min 60.4 ± 32.5 59.9 ± 22.8 67.6 ± 24.6 <0.38
NT-proBNP, ng/L 568 ± 919b 8329 ± 10342 4497 ± 4852a <0.0001
Troponin, ng/L 0.03 ± 0.03b 0.19 ± 0.25 0.16 ± 0.14 <0.004
ASBP, mm Hg 130.4 ± 26.9c 112.5 ± 18.0 120.6 ± 25.4 <0.01
ADBP, mm Hg 74.6 ± 10.9c 67.5 ± 10.6 73.7 ± 11.9 <0.01
NYHA class
I 34 (100%) 6 (13%)d 10 (21%)e <0.0001
II 0 22(49%) 18(38%)
III 0 11(25%) 20(41%)
IV 0 6(13%) 0
Abbreviations: ADBP, arterial diastolic blood pressure; ASBP, arterial systolic blood pressure; BSA, body surface area; C-AL, cardiac AL amyloidosis; GFR,
glomerular filtration rate; NC-AL, noncardiac AL amyloidosis; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Associationn;
TTR, transthyretin-related amyloidosis.
Scheffe’s post hoc analysis:
aTTR vs others, P < 0.05. bNC-AL vs others, P < 0.05; cNC-AL vs C-AL, P < 0.05. χ2 analysis: dC-AL vs NC-AL, P < 0.0001. eTTR vs C-AL, P < 0.05.
patients compared to NC-AL patients, whereas no significant
difference was observed between the TTR and C-AL groups.
A significant increase in PASP values was observed in both
C-AL and TTR patients.
Reproducibility
The interobserver variability was 4% and 5% for mitral annu-
lus E′ and E/E′, whereas it was 8% and 9% for tricuspidal
annular S′ and E/E′, respectively. Regarding 2-dimensional
speckle strain–derived analysis, the interobserver vari-
ability was 6% for LV longitudinal strain and 8% for RV
longitudinal strain.
Discussion
Our study performed a thorough and technologically
updated evaluation of RV-LV morphology and systolic and
diastolic functions in patients affected by both TTR and AL
amyloidosis.
According to the echocardiographic phenotype, we can
characterize 2 different scenarios: in our series, at time
of diagnosis, nearly half of AL patients do not present
cardiac involvement, according to the echocardiographic
international criteria. On the other hand, in our population,
ATTR was diagnosed when cardiac involvement was already
clearly evident at echocardiography in 100% of patients. A
possible reason of this significant dichotomy might be the
different diagnostic route to get to diagnosis. Although
nearly the whole population of TTR patients followed a
cardiological diagnostic route, in almost one-third of patients
affected by AL amyloidosis, the diagnosis was pointed out
after a hematological or a nephrological evaluation.
Apart from AL patients without echocardiographic
involvement, the 2 groups with cardiac involvement (C-
AL and TTR) presented a significantly different cardiac
phenotype.
ATTR patients presented increased dimension of both
LV and RV chambers with larger atrium and higher LV
and RV wall thickness. Moreover, patients with ATTR
showed impaired LV EF and FS, whereas patients with
AL amyloidosis still had normal values. At diagnosis, both
C-AL and ATTR patients presented a significant impairment
of LV and RV systolic function assessed by speckle
strain, with significant reduction in biventricular systolic
longitudinal function. Furthermore, both C-AL and ATTR
patients presented a significant and comparable impairment
of both RV and LV diastolic function assessed by TDI
echocardiography.
Despite the above-mentioned characteristics, it might
appear somehow unexpected that, in comparison to C-AL
patients, ATTR patients showed significantly less HF symp-
toms according to the NYHA functional class classification,
and significantly reduced NT-proBNP plasma values.
Our data show that ATTR patients present at diagnosis a
more advanced degree of amyloidotic heart involvement (in
terms of wall thickness, which can be regarded as an approx-
imation of the extent of amyloid deposition), but at the same
time, less severe symptoms and biohumoral signs of HF.
According to our findings, it is clearly evident that
2 different relationships between HF symptoms and
echocardiographic findings exist, based on the etiology
of the disease. In ATTR amyloidosis, a manifest diver-
gence between severity of HF symptoms and cardiac
morphological involvement shows up. On the other hand,
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Table 2. Left Ventricular Echocardiographic Characteristic of Studied Population
NC-AL, N = 34 C-AL, N = 45 TTR, N = 48 P
LVEDD, mm 45.2 ± 4.3 44.9 ± 6.9 46.1 ± 5.7 <0.63
LVESD, mm 26.6 ± 4.8 29.3 ± 6.2 33.1 ± 6.7a <0.0001
FS % 41.4 ± 7.2b 34.5 ± 9.1 28.5 ± 8.7a <0.0001
IVS, mm 10.3 ± 0.9b 15.2 ± 2.6 17.4 ± 2.7a <0.0001
LVPW, mm 10.3 ± 1.2b 15 ± 2.2 16.3 ± 2.1a <0.0001
LV mass index, g/m2 97.1 ± 19.3b 163.3 ± 36.2 197.4 ± 49.6a <0.0001
LA area, cm2 18.7 ± 3.7b 22.7 ± 3.8 26.6 ± 5a <0.0001
LVEDV, mL 80.3 ± 18.6 81.1 ± 27.1 88.5 ± 24.5 <0.23
LVESV, mL 32.6 ± 12.5 34.9 ± 15.8 46.1 ± 20.7a <0.001
EF % 59.6 ± 8.8 57.6 ± 9.2 49.1 ± 12.1a <0.0001
LV long strain % −16.8 ± 7.7b −10 ± 4.2 −8.1 ± 3.7 <0.0001
Valve thickening, yes/no 4 (12%)/30 (88%) 22 (49%)/23 (51%) 29 (60%)/19 (40%) <0.0001
Pericardial effusion, yes/no 1 (3%)/33 (97%) 13 (30%)/32 (70%) 12 (25%)/36 (75%) <0.0001
Mitral regurgitation, mild–moderate/severe 32 (94%)/2 (6%) 35 (78%)/10 (22%) 39 (81%)/9 (19%) <0.14
E, cm/s 70.4 ± 18.9 78.5 ± 20.2 80.9 ± 17.1a <0.04
A, cm/s 85.2 ± 21.4b 58.6 ± 24.9 46.3 ± 22.7 <0.0001
E/A 0.84 ± 0.2b 1.62 ± 0.9 2.12 ± 1.0a <0.0001
DT, ms 217.7 ± 68.5 195.1 ± 80 178.9 ± 66 <0.06
E′ cm/s 7.1 ± 1.9b 4.6 ± 1.3 4.6 ± 1.5 <0.0001
E/E′ 9.9 ± 3.4b 18.1 ± 7.1 19.3 ± 6.5 <0.0001
AET, ms 289.2 ± 31.7b 253.8 ± 37.6 264.3 ± 35.3 <0.0001
LV MPI 0.36 ± 0.14b 0.52 ± 0.21 0.57 ± 0.21 <0.0001
Abbreviations: A, late diastolic mitral peak flow velocity; AET, aortic valve ejection time; C-AL, cardiac AL amyloidosis; DT, decelleration time; E,
early diastolic mitral peak flow velocity; E′, early diastolic peak velocity at lateral mitral annulus; FS, fractional shortening; EF, ejection fraction; IVS,
interventricular septum thickness; LA, left atrium; LV, left ventricular; LVEDD, LV end-diastolic diameter; LVEDV, LV end-diastolic volume; LVESD, LV
end-systolic diameter; LVESV, LV end-systolic volume; LV long strain, LV longitudinal 2-dimensional-speckle strain; LVPW, posterior wall thickness; MPI,
myocardial performance index; NC-AL, noncardiac AL amyloidosis; TTR, transthyretin-related amyloidosis.
Scheffe’s post hoc analysis:
aTTR vs others, P < 0.05. bNC-AL vs others, P < 0.05.
in the AL group, the severity of clinical symptoms increased
directly with cardiac involvement.
In accordance with this hypothesis, it has already been
demonstrated5,18,19 that ATTRm and ATTRwt amyloidosis
have better prognoses, despite patients’ older age at
diagnosis and echocardiographic evidence of thicker
ventricles, with an overall survival at 2 years of 63% for
AL, 98% for ATTRm, and 100% for ATTRwt.3
More recently, Quarta and colleagues confirmed the fact
that prognosis reflects the etiology of the disease in a large
series of patients including AL, ATTRm, and ATTRwt.26
Moreover, these authors corroborated the utility of the
use of longitudinal strain to characterize the differences
in the cardiac involvement of the 3 forms of amyloidosis.
Similar to our study, they found that AL patients showed
lower wall thickness and LV mass despite worse prognostic
outcome.
The worse clinical outcome of AL amyloidosis patients
and the presence of more symptoms of HF together with
higher NT-proBNP plasma levels, despite a lower degree
of myocardial infiltration, might be related to the direct
cardiotoxic effect of circulating light chains. Animal studies
have shown that the infusion of amyloidogenic light chains
into isolated mice hearts results in cardiac dysfunction,
probably mediated by the increase in cellular oxidative
stress.27,28 Moreover, Migrino and colleagues demonstrated
that brief exposure to physiological amounts of circulating
light chain can induce endothelial dysfunction in human
adipose and coronary arterioles, and increase the apoptotic
injury in coronary artery endothelial cells, likely as a result
of oxidative stress, reduced nitric oxide bioavailability, and
production of peroxynitrite.29
Because of the cross-sectional design of our study, we can
only speculate about the hypothesis that TTR amyloidosis
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N = 45 TTR, N = 48 P
RVFW, mm 5.9 ± 1.4a 7.4 ± 1 8.7 ± 1.5b <0.0001
RVEDD, mm 26.5 ± 5.9 28.8 ± 5.1 32.4 ± 6.3b <0.0001
E tricuspid, cm/s 47.2 ± 10.2 47.5 ± 13.8 48.2 ± 13.9 <0.94
A tricuspid, cm/s 45.2 ± 12.1 44.7 ± 13.7 42.2 ± 18.4 <0.71
E/A tricuspid 1.1 ± 0.33 1.3 ± 1.1 1.2 ± 0.8 <0.51
E′ tricuspid, cm/s 10.2 ± 2.5a 7.1 ± 2.9 8.1 ± 3.2 <0.0001
E/E′ tricuspid 4.9 ± 1.6a 8.1 ± 4.8 7.8 ± 4.3 <0.009
S′ tricuspid, cm/s 13.1 ± 3.3a 10.1 ± 2.7 8.7 ± 3.3 <0.0001
TAPSE, mm 22.9 ± 3.4a 16.8 ± 4.1 15.8 ± 3.7 <0.0001
PET, ms 279 ± 27.3 263.9 ± 39 276.2 ± 39.1 <0.15
RV MPI 0.32 ± 0.16 0.45 ± 0.26 0.51 ± 0.31c <0.01
PASP, mm Hg 27.5 ± 8.1a 39.5 ± 11.9 40.6 ± 11.8 <0.0001
RV longitudinal strain % −16.8 ± 7.7a −10 ± 4.2 −8.1 ± 3.7 <0.0001
Abbreviations: A, late diastolic trans tricuspidal diastolic flow; C-AL,
cardiac AL amyloidosis; E, early peak transtricuspid diastolic flow; E′,
lateral tricuspid annulus-derived early diastolic flow; MPI, myocardial
performance index; NC-AL, noncardiac AL amyloidosis; PASP, pulmonary
artery systolic pressure; PET, pulmonary valve ejection time; RV, right
ventricular; RVEDD, RV end-diastolic diameter; RVFW, RV free wall
thickness; S′, lateral tricuspid annulus peak systolic velocity; TAPSE,
tricuspid annulus systolic plane excursion; TTR, transthyretin-related
amyloidosis.
Scheffe’s post hoc analysis:
aNC-AL vs others, P < 0.05. bTTR vs others, P < 0.05. cNC-AL vs C-AL,
P < 0.05.
could be a less aggressive disease with a slower progressive
course, probably due to the lower deposition rate of
the amyloid protein and to the absence of the intrinsic
cardiotoxic effect of circulating light chains. In ATTR, a
slower deposition of amyloid fibers could let the heart
predispose compensatory mechanisms that might slow
down the onset of HF symptoms, justifying the lower NT-
proBNP plasma levels. In addition, a lesser extent of a direct
toxic effect might be postulated to explain these results.
Limitations
The study presents all the limitations of a cross-sectional
design. As no survival data analysis was performed,
longitudinal observational studies are needed to determine
the prognostic value of the echocardiographic differences
detected at baseline.
Our choice to group together ATTRm and ATTRwt
patients might be criticized. However, in our population,
the ATTRm and the ATTRwt phenotypes were similar in
terms of cardiac involvement, echocardiographic profile,
and age at diagnosis. A second limitation is the lack of biopsy
evidence of amyloid in 32% of ATTRwt amyloidosis patients.
However, this cohort of patients was fully characterized with
all other clinical investigative techniques currently available.
When combined, these are known to provide high diagnostic
accuracy.30,31
Conclusion
On the basis of the aforementioned considerations, we may
hypothesize that we are observing different diseases at
a different temporal point of view. AL amyloidosis has a
quick progression rate, becomes rapidly symptomatic, and
the involvement of other organs can help the diagnostic
process. On the other hand, TTR amyloidosis could have
a slow progression rate, remaining poorly symptomatic
for a greater amount of time. In addition, especially in our
population, in which ATTRm has mostly a cardiac phenotype
with late onset,32 therefore being comparable with ATTRwt,
the absence of neurological manifestations or other major
organ system involvement may be a further cause of under-
recognition. The validity of our considerations should be
corroborated by longitudinal observations starting from
ATTRm carriers.
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